267413-27-4

Basic information

• Product Name: (1-Methyl-1H-indazol-5-yl)methylamine
• Synonyms: (1-Methyl-1H-indazol-5-yl)methylamine;5-(Aminomethyl)-1-methyl-1H-indazole;(1-Methyl-1H-indazol-5-yl)MethanaMine
• CAS NO: 267413-27-4
• Molecular Formula: C₉H₁₁N₃
• Molecular Weight: 161.20374
• Mol File: 267413-27-4.mol

Chemical Properties

• Boiling Point: 312.5±17.0 °C(Predicted)
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.94±0.50(Predicted)
• CAS DataBase Reference: (1-Methyl-1H-indazol-5-yl)methylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (1-Methyl-1H-indazol-5-yl)methylamine(267413-27-4)
• EPA Substance Registry System: (1-Methyl-1H-indazol-5-yl)methylamine(267413-27-4)

Safety Data

• Hazardous Substances Data: 267413-27-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1-Methyl-1H-indazol-5-yl)methylamine is used as an anticancer agent for its ability to induce apoptosis in cancer cells. It operates by disrupting the interaction between MDM2 and p53, which results in the activation of the p53 tumor suppressor pathway, a key mechanism in preventing the proliferation of cancer cells.
Used in Cancer Research:
In cancer research, (1-Methyl-1H-indazol-5-yl)methylamine is utilized to study the mechanisms of MDM2-p53 interaction and its role in tumorigenesis. This helps in understanding the pathways that can be targeted for developing novel therapeutic strategies against cancer.
Used in Drug Resistance Overcoming:
(1-Methyl-1H-indazol-5-yl)methylamine is also used in the development of treatments aimed at overcoming resistance to existing cancer therapies. Its potential to reactivate the p53 pathway could make it a valuable component in combination therapies for cancers that have developed resistance to standard treatments.
Used in Treatment of Various Cancer Types:
(1-Methyl-1H-indazol-5-yl)methylamine is being investigated for its therapeutic potential across a range of cancer types. Its mechanism of action suggests that it could be applicable in the treatment of various malignancies where the p53 pathway is disrupted, offering a new avenue for cancer treatment.

Relevant articles and documents

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2or N; d is CY3or N; e is CY4or N; f is CY5or N; g is CY6or N; Y4, Y5, and Y6are independently hydrogen, C1-4alkyl, or halogen; Y1and Y2are independently hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, NH2, OH or C1-4alkoxy, and Y3is hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, —CN, NH2, OH or C1-4alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.

THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is N Y 1 or O; c is CY 2 or N; d is CY 2; e is CY 1 or N; f is CY 1 or N; g is CY 1 or N; Y 1 is hydrogen, C 1-4 alkyl, or halogen; Y 2 is hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, halogen, NH 2, OH or C 1-4 alkoxy;A is and W, X, Z, R 3, R 4 and R 5 are defined in the specification.